EML4 and non-small cell lung carcinoma: Alectinib also inhibits the ALK-G1269A mutation, which is a secondary mutation found in EML4-ALK positive crizotinib refractory NSCLC patients comparable well-compared with crizotinib and in the similar range as we have observed earlier with brigatinib (47).